New Treatment Recommended for Asian Chronic Hepatitis C Patients | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Tattoo, Piercing Shop Creates HIV and Hepatitis Risk

Back to News Homepage
Next

Alinia Tablets and Hepatitis C

New Treatment Recommended for Asian Chronic Hepatitis C Patients

The Editors at Hepatitis Central
August 15, 2007

Print this page

The Chinese University of Hong Kong recently made public the results of its three-year study, which evaluated the use of interferon beta-1a and its combination with ribavirin in the treatment of Asian chronic Hepatitis C patients. Find out how it compares to the existing peginterferon-alfa based therapy.

New treatment for chronic hepatitis C leads to less side effects: study

http://english.people.com.cn

A study result made public Monday by the Chinese University of Hong Kong reveals that combination of interferon beta-1a and ribavirin treatment for chronic hepatitis C creates less side effects.

Chronic hepatitis C is an important cause of liver cirrhosis and liver cancer. Currently, the standard treatment of chronic hepatitis C is combination of peginterferon-alfa and ribavirin, which, however, leads to common adverse effects including fever and flu-like symptoms, injection site reaction, depression and bone marrow suppression. This decreases patients’ compliance and in turn reduces the treatment effect, the university said.

The university hence carried out a three-year study to assess the use of interferon beta-1a and its combination with ribavirin in the treatment of Asian chronic hepatitis C patients.

About 250 Asian chronic hepatitis C patients with active disease were recruited and randomly assigned into two groups which received placebo treatment and interferon beta-1a plus ribavirin combination treatment respectively for 12 weeks, it said.

The result shows that interferon beta-1a and ribavirin combination treatment can achieve a similar rate of viral clearance but a low rate of adverse event and patient discontinuation as compared to the existing peginterferon-alfa based treatment.

The university recommended that interferon-beta-1 and ribavirin combination treatment be considered as an alternative to the existing peginterferon-alfa based therapy for Asian patients with chronic hepatitis C infection.

Source: Xinhua

No Comments - be the first!
Share
Share
Previous

Tattoo, Piercing Shop Creates HIV and Hepatitis Risk

Back to News Homepage
Next

Alinia Tablets and Hepatitis C

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.